Liposomes: Vehicles for the targeted and controlled delivery of peptides and proteins

Journal of Controlled Release

Volumn 46, Issue 1-2, 1997, Pages 165-175

  Crommelin, D J A ^a   Daemen, T ^b   Scherphof, G L ^b   Vingerhoeds, M H ^a   Heeremans, J L M ^a   Kluft, C ^c   Storm, G ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c TNO   (Netherlands)

Author keywords

(Immuno)liposomes; Cytostatics; Drug targeting; Fibrinolysis; Immunomodulation

Indexed keywords

CYTOSTATIC AGENT; DRUG VEHICLE; GROWTH FACTOR; IMMUNOLIPOSOME; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN DERIVATIVE; LIPOSOME; MURAMYL PEPTIDE;

ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; FIBRINOLYSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE ACTIVATION; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0031054859     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(96)01583-0     Document Type: Conference Paper

References (62)

1. G. Storm, C. Oussoren, P.A.M. Peeters and Y. B., Tolerability of liposomes in vivo, in: G. Gregoriadis (Ed.), Liposome Technology, CRC Press, Inc., Boca Raton, 1993, pp. 345-383.
2. M.N.J.Z. Grit and D.J.A. Crommelin, Analysis and hydrolysis kinetics of phospholipids in aqueous liposome dispersions, in: G. Gregoriadis (Ed.), Liposome Technology, CRC Press, Boca Raton, FL, 1993, pp. 165-198.
3. D.J.A. Crommelin, H. Talsma, M. Grit and N.J. Zuidam, Physical stability on long term storage, in: G. Cevc (Ed.), Handbook of Phospholipids, Marcel Dekker, New York, 1993, pp. 335-348.
4. D.J.A. Crommelin and H. Schreier, Liposomes, in: J. Kreuter (Ed.), Colloidal Drug Delivery Systems, Marcel Dekker, New York, 1994, pp. 73-190.
5. Y. Barenholz and D.J.A. Crommelin, Liposomes as pharmaceutical dosage forms, in: J. Swarbrick and B.J.C. (Eds), Encyclopedia of Pharmaceutical Technology, Marcel Dekker, New York, 1994, pp. 1-39.
6. I.W. Seymour, Passive tumor targeting of soluble macromolecules and drug conjugates, Crit. Rev. Ther. Drug Carrier Syst. 9 (1992) 135-187.
7. I.A.J.M. Bakker-Woudenberg, A.F. Lokerse, M.T. Ten Kate and G. Storm, Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue, Biochim. Biophys. Acta 1138 (1992) 318-326.
8. I.A.J.M. Bakker-Woudenberg, A.F. Lokerse, M.T. Ten Kate, J.W. Mouton, M.C. Woodle and G. Storm, Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae infected lung tissue, J. Infect. Dis. 168 (1993) 164-171.
9. G.C. Blume, D.J.A. Crommelin, I.A.J.M. Bakker-Woudenberg, C. Kluft and G. Storm, Specific targeting with poly-ethyleneglycol-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times, Biochim. Biophys. Acta 1149 (1993) 180-184.
10. G.L. Scherphof, H. Morselt and T. Allen, Intrahepatic distributions of long-circulating liposomes containing poly-(ethylene glycol) distearoyl phosphatidylethanolamine, J. Liposome Res. 4 (1994) 213-228.
11. D.D. Lasic and F.J. Martin, Stealth® Liposomes, CRC Press, Boca Raton, FL, 1995.
12. O. Boerman, W.J.G. Van Oyen, F.J.G. Corstens, D.J.A. Crommelin and G. Storm, PEG-coated liposomes labeled with indium-111 as infection imaging agent, J. Nucl. Med. 36 (1995) 1639-1644.
13. M.S. Roh, M.P. Kahky, C. Oyedeji, J. Klostergaard, L. Wang, S.A. Curley and E. Lotzova, Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases, Clin. Exp. Metastas. 10 (1992) 317-327.
14. I.J. Fidler, Macrophages and metastases: a biological approach to cancer therapy, Cancer Res. 45 (1985) 4714-4726.
15. T. Daemen, Activation of Kupffer cells tumoricidal activity by immunomodulators encapsulated in liposomes, in: 41st Forum in Immunology, Inst. Pasteur, Elsevier, Paris 1992, pp. 211-214.
16. T. Daemen, A. Veninga, J. Dijkstra and G. Scherphof, Differential effects of liposome incorporation on macrophage-activating potencies of LPS, Lipid A and MDP; differences in susceptibility to lysosomal enzymes, J. Immunol. 142 (1989) 2469-2474.
17. T. Daemen, A. Veninga, F.H. Roerdink and G.L. Scherphof, In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide, Cancer Res. 46 (1986) 4330-4335.
18. T. Daemen, A. Veninga, F.H. Roerdink and G.L. Scherphof, Conditions controlling tumorcytotoxicity of rat liver macrophages mediated by liposomal muramyl dipeptide, Biochim. Biophys. Acta 991 (1989) 145-151.
19. T. Daemen, B.H.J. Dontje, A. Veninga, G.L. Scherphof and J.W. Oosterhuis, Therapy of murine liver metastases by administration of MDP encapsulated in liposomes, Select. Cancer Ther. 6 (1990) 63-72.
20. C. Thomas, A.M. Nijenhuis, B. Dontje, T. Daemen and G.L. Scherphof, Tumoricidal response of liver macrophages isolated from rats bearing liver metastases of colon adenocarcinoma, J. Leukocyte Biol. 57 (1995) 617-623.
21. R.M.J. Hoedemakers, D.P. Vossebel, T. Daemen and G.L. Scherphof, Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome encapsulated muramyl peptides, J. Immunother. 13 (1993) 252-260.
22. R.M.J. Hoedemakers, G.L. Scherphof and T. Daemen, Repeated intravenous administration of liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine diminishes cytotoxic potential of the rat liver macrophage population, J. Liposome Res. 5 (1995) 581-604.
23. T. Daemen, A. Veninga, F.H. Roerdink and G.L. Scherphof, Endocytic and tumoricidal heterogeneity of rat liver macrophage populations; implications for drug targeting, Select. Cancer Ther. 5 (1989) 157-168.
24. R.M.J. Hoedemakers, H.W.M. Morselt, G.L. Scherphof and T. Daemen, Heterogeneity in secretory responses of rat liver macrophages of different cell size, Liver 15 (1995) 313-319.
25. R.J. Hoedemakers, J.E. Atmosoerodjo-Briggs, H.W.M. Morselt, T. Daemen, G.L. Scherphof and M.J. Hardonk, Histochemical and electron microscopic characterization of hepatic macrophage subfractions isolated from normal and liposomal muramyl dipeptide treated rats, Liver 15 (1995) 113-120.
26. T. Daemen, B.H.J. Dontje, A. Veninga, G.L. Scherphof and J.W. Oosterhuis, Therapy of murine liver metastases by administration of MDP encapsulated in liposomes, Select. Cancer Ther. 6 (1990) 63-72.
27. T. Daemen, J. Regts, H. Morselt and G.L. Scherphof, The effect of liver macrophages on in vitro cytolytic activity of 5FU and FUdR on colon carcinoma cells; evidence of macrophage activation, Int. J. Immunopharmacol. 14 (1992) 857-864.
28. T. Daemen, B.H.J. Dontje, J. Regts and G.L. Scherphof, Chemo-immunotherapy of murine liver metastases with 5FU in combination with liposome-encapsulated MDP, J. Immunother. 13 (1993) 31-35.
29. T. Daemen, G. Hofstee, M. Ten Kate, I. Bakker-Woudenberg and G.L. Scherphof, Liposomal doxorubicin is highly toxic to rat liver macrophage, Int. J. Cancer 61 (1995) 716-721.
30. D.J.A. Crommelin, G. Scherphof and G. Storm, Active targeting with particulate carrier systems in the blood compartment, Adv. Drug Deliv. Rev. 17 (1995) 49-60.
31. D. Collen, Fibrin-selective thrombolytic therapy for acute myocardial infarction, Circulation 93 (1996) 857-865.
32. J.L.M. Heeremans, J.J. Kraaijenga, P. Los, C. Kluft and D.J.A. Crommelin, Development of a procedure for coupling the homing device glu-plasminogen to liposomes, Biochim. Biophys. Acta 1117 (1992) 258-264.
33. J.T.P. Derksen and G.L. Scherphof, An improved method for the covalent coupling of proteins to liposomes, Biochim. Biophys. Acta 814 (1985) 151-155.
34. J.L.M. Heeremans, C. Kluft and D.J.A. Crommelin, Pharmaceutical composition for the site-specific release of a clot-dissolving protein and method for the preparation thereof, (1992). Int. Patent Applic. WO 94/07537.
35. J.L.M. Heeremans, F.W. Mijnheer, H.R. Gerritsen, R. Prevost, C. Kluft and D.J.A. Crommelin, Long-term stability of liposomes containing both tissue-type plasminogen activator and glu-plasminogen, Int. J. Pharm. 129 (1996) 191-202.
36. J.L.M. Heeremans, H.R. Gerritsen, S.P. Meusen, F.W. Mijnheer, R.S. Gangaram Panday, R. Prevost, C. Kluft and D.J.A. Crommelin, The preparation of tissue-type plasminogen activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage, J. Drug Targeting 3 (1996) 301-310.
37. J.L.M. Heeremans, R. Prevost, M.E.A. Bekkers, P. Los, J.J. Emeis, C. Kluft and D.J.A. Crommelin, Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA, Thromb. Haemostas. 73 (1995) 488-494.
38. P.G.M. Bloemen, P.A.J. Henricks, L. Van Bloois, M.C. Van den Tweel, A.C. Bloem, F.P. Nijkamp, D.J.A. Crommelin and G. Storm, Adhesion molecules: a new target for immunoliposome-mediated drug delivery, FEBS Lett. 357 (1995) 140-144.
39. U.K. Nässander, P.A. Steerenberg, H. Poppe, G. Storm, P.H.K. Jap, L.G. Poels, W.H. De Jong and D.J.A. Crommelin, In vivo targeting of OV-TL3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice, Cancer Res. 52 (1992) 646-653.
40. M.H. Vingerhoeds, G. Storm and D.J.A. Crommelin, Immunoliposomes in vivo, Immunomethods 4 (1994) 259-272.
41. G. Storm, U.K. Nässander, M.H. Vingerhoeds, P.A. Steerenberg and D.J.A. Crommelin, Antibody-targeted liposomes to deliver doxorubicin to ovarian cancer cells, J. Liposome Res. 4 (1994) 641-666.
42. U.K. Nässander, P.A. Steerenberg, W.H. De Jong, W.O.W.M. Van Oosterveld, C.M.E. Te Boekhorst, L.G. Poels, P.H.K. Jap and G. Storm, Immunoliposomes directed against human ovarian carcinoma, Biochim. Biophys. Acta 1235 (1995) 126-139.
43. R. Bron, A. Ortiz, J. Dijkstra, T. Stegmann and J. Wilschut, Preparation, properties and applications of reconstituted influenza virus envelopes (virosomes), in: N. Düzgünes (Ed.), Membrane Fusion Techniques, Part A, Academic Press, San Diego, CA, 1993, pp. 313-331.
44. P. Schoen, R. Bron and Wilschut, Delivery of foreign substances to cells mediated by fusion-active reconstituted influenza virus envelopes (virosomes), J. Liposome Res. 3 (1993) 767-792.
45. M.H. Vingerhoeds, M.J. Haisma, M. Van Muijen, R.B.J. Van de Rijt, D.J.A. Crommelin and G. Storm, A new application for liposomes in cancer therapy: immunoliposomes bearing enzymes (immuno-enzymosomes) for site specific activation of prodrugs, FEBS Lett. 336 (1993) 485-490.
46. K.D. Bagshawe, Antibody-directed enzyme prodrug therapy (Adept), J. Control. Release 28 (1994) 187-193.
47. H.J. Haisma, E. Boven, M. Van Muijen, J. de Jong, W.J.F. Van der Vijgh and H.M. Pinedo, A monoclonal antibody-b-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer, Br. J. Cancer 66 (1992) 474-478.
48. M.H. Vingerhoeds, H.J. Haisma, S.O. Belliot, R.H.P. Smit, D.J.A. Crommelin and G. Storm, Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): Optimization of prodrug activating capacity, Pharm. Res. 13 (1996) 604-610.
49. J.L.M. Heeremans, R. Prevost, P. Los, C. Kluft and D.J.A. Crommelin, Binding of liposomal glu-plasminogen to fibrin in vitro: comparison to and competition with free glu-plasminogen, Proc. Int. Symp. Control. Release Bioact. Mater. 21 (1994) 232-233.
50. M.C. Woodle, G. Storm, M.S. Newman, J. Jekot, L.R. Collins, F.J. Martin and F.C. Szoka, Prolonged systemic delivery of peptide drugs by long circulating liposomes: illustration with vasopressin in the Brattleboro rat, Pharm. Res. 9 (1992) 260-265.
51. P.A.M. Peeters, B.G. Brunink, W.M.C. Eling and D.J.A. Crommelin, Therapeutic effect of chloroquine (CQ) containing liposomes or combinations of antibodies and CQ or liposomal CQ in rats infected with Plasmodium berghei parasitized mouse red blood cells, Biochim. Biophys. Acta 981 (1989) 269-276.
52. P.A.M. Peeters, C.A.M. Claessens, W.M.C. Eling and D.J.A. Crommelin, Immunospecific targeting of liposomes to erythrocytes, Biochem. Pharmacol. 37 (1988) 2215-2222.
53. P.A.M. Peeters, C. Oussoren, W.M.C. Eling and D.J.A. Crommelin, Immunospecific targeting of immunoliposomes, F(ab′)2 and IgG to red blood cells in vivo, Biochim. Biophys. Acta 943 (1988) 137-147.
54. J.A.A.M. Kamps, H.W.M. Morsell, P.J. Swart, M. Wilkens, D.K.F. Meijer and G.L. Scherphof, (1996). Targeting of liposomes to non-parenchymal liver cells by means of covalently coupled anionized albumins, J. Liposome Res. 6 (1996) 255.
55. T. Daemen, R. Hoedemakers, G. Storm and G.L. Scherphof, Opportunities in targeted drug delivery to Kupffer cells: delivery of immunomodulators to Kupffer cells-activation of tumoricidal properties, Adv. Drug Deliv. Rev. 17 (1995) 21-30.
56. C. Oussoren, Subcutane toediening van cytostatica ingebouwd in liposomen voor de behandeling van lymfatische metastasen, Pharm. Weekblad 130 (1995) 605-609.
57. F. Kadir, J. Zuidema and D.J.A. Crommelin, Liposomes as intramuscular and subcutaneous injection drug delivery systems, in: A. Rolland (Ed.), Pharmaceutical Particulate Carriers, Therapeutic Applications, Marcel Dekker, New York, 1992, pp. 165-198.
58. F. Kadir, W.M.C. Eling, D.J.A. Crommelin and J. Zuidema, Influence of injection volume on the release kinetics of liposomal chloroquine administered intramuscularly or subcutaneously to mice, J. Control. Release 17 (1991) 277-284.
59. F. Kadir, W.M.C. Eling, D.J.A. Crommelin and J. Zuidema, Kinetics and prophylactic efficacy of increasing dosages of liposome-encapsulated chloroquine after intramuscular injection in mice, J. Control. Release 20 (1992) 47-54.
60. J.J. Bergers, W Den Otter, H.F.J. Dullens, J.W. De Groot, P.A. Steerenberg, P.M.G. Filius and D.J.A. Crommelin, Effect of immunomodulators on specific tumor immunity induced by liposome-encapsulated tumor-associated antigens, Int. J. Cancer 56 (1994) 721-726.
61. J.J. Bergers, W Den Otter, H.F.J. Dullens, J.W. De Grool, PA. Steerenberg, M.W.H. Mimpen and D.J.A. Crommelin, Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice. Cancer Immunol. Immunother. 37 (1993) 271-279.
62. G.F.A. Kersten and D.J.A. Crommelin, Liposomes and iscoms as vaccine formulations, Biochim. Biophys. Acta 1241 (1995) 117-138.